MedTrace Logo

Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D

NCT03105310 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-04-07

No results posted yet for this study

Summary

Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry, that include two hydrophobes and one hydrogen bond acceptor.

The aim of the study io evaluate the utility of Ezetimibe in combination with pegylated interferon in patients with chronic HDV infection.

Conditions

  • Hepatitis D, Chronic

Interventions

DRUG

Pegylated interferon alfa

Pegylated interferon alfa

DRUG

Ezetimibe

Ezetimibe

Sponsors & Collaborators

  • Aga Khan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-12-31
Completion
2017-06-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03105310 on ClinicalTrials.gov